Literature DB >> 11192624

Elevated plasma levels of transforming growth factor beta1 in patients with muscular dystrophy.

M Ishitobi1, K Haginoya, Y Zhao, A Ohnuma, J Minato, T Yanagisawa, M Tanabu, M Kikuchi, K Iinuma.   

Abstract

The progression of muscular weakness of patients suffering from muscular dystrophies directly correlates with the progressive loss of myofibers, accompanied by fibrosis. Since transforming growth factor beta1 (TGF-beta1) promotes tissue fibrosis, we measured the plasma TGF-beta1 level in patients with various muscular dystrophies in order to determine whether the level is elevated in patients with muscular dystrophy and if the level reflects the severity of tissue fibrosis. The plasma TGF-beta1 level was significantly elevated in patients with Duchenne muscular dystrophy and congenital muscular dystrophy (CMD), but not in those with Becker muscular dystrophy. Growth factors related to muscle fiber regeneration and fibrosis might be a key factor in the progression of muscular dystrophy and could be a target for therapeutic studies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11192624     DOI: 10.1097/00001756-200012180-00026

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  17 in total

1.  Pentoxifylline as a rescue treatment for DMD: a randomized double-blind clinical trial.

Authors:  D M Escolar; A Zimmerman; T Bertorini; P R Clemens; A M Connolly; L Mesa; K Gorni; A Kornberg; H Kolski; N Kuntz; Y Nevo; C Tesi-Rocha; K Nagaraju; S Rayavarapu; L P Hache; J E Mayhew; J Florence; F Hu; A Arrieta; E Henricson; R T Leshner; J K Mah
Journal:  Neurology       Date:  2012-03-07       Impact factor: 9.910

2.  Exercise-induced changes in circulating levels of transforming growth factor-beta-1 in humans: methodological considerations.

Authors:  Katja Heinemeier; Henning Langberg; Michael Kjaer
Journal:  Eur J Appl Physiol       Date:  2003-07-09       Impact factor: 3.078

3.  Effects of T-lymphocyte depletion on muscle fibrosis in the mdx mouse.

Authors:  Jamie Morrison; Donald B Palmer; Stephen Cobbold; Terence Partridge; George Bou-Gharios
Journal:  Am J Pathol       Date:  2005-06       Impact factor: 4.307

4.  Can Wharton jelly derived or adipose tissue derived mesenchymal stem cell can be a treatment option for duchenne muscular dystrophy? Answers as transcriptomic aspect.

Authors:  Eda Sun; Erdal Karaoz
Journal:  Am J Stem Cells       Date:  2020-08-25

5.  Angiotensin II type 1 receptor antagonists alleviate muscle pathology in the mouse model for laminin-α2-deficient congenital muscular dystrophy (MDC1A).

Authors:  Sarina Meinen; Shuo Lin; Markus A Ruegg
Journal:  Skelet Muscle       Date:  2012-09-03       Impact factor: 4.912

6.  Role of TGF-β signaling in inherited and acquired myopathies.

Authors:  Tyesha N Burks; Ronald D Cohn
Journal:  Skelet Muscle       Date:  2011-05-04       Impact factor: 4.912

7.  Novel approach to meta-analysis of microarray datasets reveals muscle remodeling-related drug targets and biomarkers in Duchenne muscular dystrophy.

Authors:  Ekaterina Kotelnikova; Maria A Shkrob; Mikhail A Pyatnitskiy; Alessandra Ferlini; Nikolai Daraselia
Journal:  PLoS Comput Biol       Date:  2012-02-02       Impact factor: 4.475

8.  Increase in decorin and biglycan in Duchenne Muscular Dystrophy: role of fibroblasts as cell source of these proteoglycans in the disease.

Authors:  Ricardo Fadic; Valeria Mezzano; Karin Alvarez; Daniel Cabrera; Jenny Holmgren; Enrique Brandan
Journal:  J Cell Mol Med       Date:  2006 Jul-Sep       Impact factor: 5.310

9.  Conditional expression of TGF-β1 in skeletal muscles causes endomysial fibrosis and myofibers atrophy.

Authors:  Jigna Narola; Sachchida Nand Pandey; Adam Glick; Yi-Wen Chen
Journal:  PLoS One       Date:  2013-11-14       Impact factor: 3.240

10.  Glucocorticoids Improve Myogenic Differentiation In Vitro by Suppressing the Synthesis of Versican, a Transitional Matrix Protein Overexpressed in Dystrophic Skeletal Muscles.

Authors:  Natasha McRae; Leonard Forgan; Bryony McNeill; Alex Addinsall; Daniel McCulloch; Chris Van der Poel; Nicole Stupka
Journal:  Int J Mol Sci       Date:  2017-12-06       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.